Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

588 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of TU-100, a traditional Japanese medicine, administered after hepatic resection in patients with liver cancer: a multi-center, phase III trial (JFMC40-1001).
Shimada M, Morine Y, Nagano H, Hatano E, Kaiho T, Miyazaki M, Kono T, Kamiyama T, Morita S, Sakamoto J, Kusano M, Saji S, Kanematsu T, Kitajima M. Shimada M, et al. Among authors: saji s. Int J Clin Oncol. 2015 Feb;20(1):95-104. doi: 10.1007/s10147-014-0678-2. Epub 2014 Mar 6. Int J Clin Oncol. 2015. PMID: 24595550 Clinical Trial.
Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Chan MS, Miki Y, Saji S, Ueno T, Toi M, Sasano H. Chanplakorn N, et al. Among authors: saji s. Breast Cancer Res Treat. 2010 Apr;120(3):639-48. doi: 10.1007/s10549-010-0785-3. Epub 2010 Feb 12. Breast Cancer Res Treat. 2010. PMID: 20151319
Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003).
Tanaka H, Kanda M, Morita S, Taguri M, Nishikawa K, Shimada M, Muguruma K, Koeda K, Takahashi M, Nakamori M, Konno H, Tsuji A, Hosoya Y, Shirasaka T, Yamamitsu S, Sowa M, Kitajima M, Okajima M, Kobayashi M, Sakamoto J, Saji S, Hirakawa K. Tanaka H, et al. Among authors: saji s. Int J Clin Oncol. 2017 Dec;22(6):1052-1059. doi: 10.1007/s10147-017-1157-3. Epub 2017 Jun 30. Int J Clin Oncol. 2017. PMID: 28667408 Free PMC article. Clinical Trial.
Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.
Toi M, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Takada M, Ueno T, Saji S, Chanplakorn N, Suzuki T, Sasano H. Toi M, et al. Among authors: saji s. Cancer Sci. 2011 Apr;102(4):858-65. doi: 10.1111/j.1349-7006.2011.01867.x. Epub 2011 Feb 10. Cancer Sci. 2011. PMID: 21231986 Free article.
A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundation for Multidisciplinary Treatment of Cancer 32).
Kusano M, Aoyama T, Okabayashi K, Hirata K, Tsuji Y, Nakamori S, Asahara T, Ohashi Y, Yoshikawa T, Sakamoto J, Oba K, Saji S. Kusano M, et al. Among authors: saji s. J Cancer Res Ther. 2018 Sep;14(Supplement):S761-S766. doi: 10.4103/0973-1482.179188. J Cancer Res Ther. 2018. PMID: 30249900 Free article. Clinical Trial.
Erratum to: Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.
Suto T, Ishiguro M, Hamada C, Kunieda K, Masuko H, Kondo K, Ishida H, Nishimura G, Sasaki K, Morita T, Hazama S, Maeda K, Mishima H, Ike H, Sadahiro S, Sugihara K, Okajima M, Saji S, Sakamoto J, Tomita N. Suto T, et al. Among authors: saji s. Int J Clin Oncol. 2017 Aug;22(4):805-806. doi: 10.1007/s10147-017-1146-6. Int J Clin Oncol. 2017. PMID: 28608229 Free PMC article. No abstract available.
Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.
Suto T, Ishiguro M, Hamada C, Kunieda K, Masuko H, Kondo K, Ishida H, Nishimura G, Sasaki K, Morita T, Hazama S, Maeda K, Mishima H, Ike H, Sadahiro S, Sugihara K, Okajima M, Saji S, Sakamoto J, Tomita N. Suto T, et al. Among authors: saji s. Int J Clin Oncol. 2017 Jun;22(3):494-504. doi: 10.1007/s10147-016-1083-9. Epub 2017 Jan 11. Int J Clin Oncol. 2017. PMID: 28078540 Free PMC article. Clinical Trial.
588 results